Patent ID: 6156794
Filing Date: 2000-12-05
Classification: A61K,A61P,C07D

Abstract:
A therapeutic method comprising preventing or treating a glutamate-related disorder in a mammal, by administering to said mammal an effective amount of a compound of the formula I: ##STR3## wherein a) R.sup.1 and R.sup.2 are individually (C.sub.1 -C.sub.8) alkyl, (C.sub.6 -C.sub.12)aryl, or heteroaryl; or R.sup.1 and R.sup.2 together with the nitrogen to which they are attached are a 4-8 membered ring optionally comprising 1, 2, or 3 additional heteroatoms selected from the group consisting of non-peroxide oxygen, sulfur, and N(R.sub.a), wherein each R.sub.a is absent or is hydrogen, (C.sub.1 -C.sub.8)alkyl, (C.sub.1 -C.sub.8)alkanoyl, phenyl, benzyl, or phenethyl; and R.sup.3 is hydrogen, (C.sub.1 -C.sub.8)alkyl, (C.sub.6 -C.sub.12)aryl, heteroaryl, SC(.dbd.S)N(R.sup.1)(R.sup.2), or a glutathione derivative; orb) R.sup.1 and R.sup.3 together are a divalent ethylene or propylene chain and R.sup.2 is (C.sub.1 -C.sub.8) alkyl, (C.sub.6-C.sub.12)aryl, or heteroaryl; orc) R.sup.1 and R.sup.2 together with the nitrogen to which they are attached are an azetidino, pyrrolidino, piperidino, hexamethyleneimin-1-yl, or heptamethylene-imin-1-yl ring, said ring being substituted on carbon by a substituent R.sub.b ; wherein R.sub.b and R.sup.3 taken together are methylene, ethylene, or a direct bond; and wherein the ring comprising R.sub.b and R.sup.3 is a five- or a six-membered ring;wherein any aryl or heteroaryl in R.sup.1, R.sup.2, or R.sup.3 may optionally be substituted with 1, 2, or 3 substituents selected from the group consisting of halo, nitro, cyano, hydroxy, (C.sub.1 -C.sub.8)alkoxy, (C.sub.1 -C.sub.8)alkanoyl, (C.sub.2 -C.sub.8)alkanoyloxy, trifluoromethyl, trifluoromethoxy, and carboxy;X is O or S; andn is 0, 1, or 2;or a pharmaceutically acceptable salt thereof.